Liver Cirrhosis - Epidemiology Forecast - 2034

Key Highlights

• The analysis indicates that Japan has the highest prevalence of diagnosed MMD cases, comprising 49% of the total in the 7MM. Following this, the United States contributes approximately 27% of the diagnosed MMD cases among the 7MM countries in 2022.
• In 2022, the Total Diagnosed Prevalent Cases of MMD in EU4 and the UK were roughly 990 thousand, representing approximately 24% of the total diagnosed MMD cases across the 7MM.
• Based on our analysis and estimations, females are predominantly more affected by MMD in the 7MM. This gender discrepancy may be influenced by various factors, including hormonal, genetic, or environmental considerations.

This report delivers an in-depth understanding of Myopic Macular Degeneration, historical and forecasted epidemiology of Myopic Macular Degeneration in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Myopic Macular Degeneration Disease Understanding

Myopic Macular Degeneration (MMD) Overview

MMD is a progressive eye condition that can cause vision loss in people with high myopia, or severe nearsightedness. The condition is characterized by the stretching and thinning of the retina, particularly in the macula region, leading to degenerative changes in the eye.

The onset of macular degeneration is strongly impacted by genetic factors. Individuals with a first-degree relative, like a parent or sibling, affected by macular degeneration face a risk greater than that of the general population. Moreover, beyond familial connections, the likelihood of developing macular degeneration mirrors a similar trend with smoking cigarettes, markedly elevating the risk.

Myopic Macular Degeneration Diagnosis

MMD is diagnosed through a comprehensive eye examination, which includes a visual acuity test, dilated fundus examination, and imaging techniques like optical coherence tomography (OCT) and fluorescein angiography. These tests help to identify the characteristic signs of MMD, such as retinal thinning, atrophy, lacquer cracks, and choroidal neovascularization (CNV).

The challenges associated with the diagnosis of MMD include the condition's slow progression, which can lead to delayed symptom recognition. Additionally, distinguishing MMD from other eye diseases, especially in the early stages, can be challenging due to overlapping symptoms. Furthermore, the rarity of MMD and the need for specialized tests like OCT and fluorescein angiography for accurate diagnosis pose additional challenges in identifying and managing this condition effectively.

Myopic Macular Degeneration Epidemiology

For the purpose of designing the patient-based model for Myopic Macular Degeneration (MMD), the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of MMD, Gender-specific Diagnosed Prevalent Cases of MMD, and Total Diagnosed Prevalent Cases of Myopic Choroidal Neovascularization (mCNV), in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per the analyst's estimations, the total diagnosed prevalent cases of MMD in the 7MM were approximately 4.1 million in 2022.

• The overall count of individuals diagnosed with MMD in the United States was approximately 1.1 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, Japan accounted for the highest number of MMD diagnosed cases of around 2 million cases in 2022. Forecasts indicate a projected decrease in the cases during the period (2023-2034).
• Among EU4 and the UK, France had the highest diagnosed prevalent population of MMD, with about 0.28 million cases, followed by Germany and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In 2022, the publisher's analysis of gender-specific diagnosed prevalent MMD cases within the 7MM indicated an approximate distribution of 39% in males and 61% in females.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Utah Hospital, US; Department of Ophthalmology, Columbia University, New York; Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Germany; Department of Ophthalmology, University of Padova, Italy; The Royal College of Ophthalmologists, London, UK; Department of Ophthalmology, Osaka University Medical School, Osaka, Japan; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Myopic Macular Degeneration, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Myopic Macular Degeneration Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of MMD
• Gender-specific Diagnosed Prevalent Cases of MMD
• Total Diagnosed Prevalent Cases of Myopic Choroidal Neovascularization (mCNV)

Myopic Macular Degeneration Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Myopic Macular Degeneration Epidemiology Segmentation

Myopic Macular Degeneration Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Myopic Macular Degeneration? What will be the growth opportunities across the 7MM concerning the patient population of Myopic Macular Degeneration?
• What is the historical and forecasted Myopic Macular Degeneration patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of MMD in Japan higher than the US?
• Which country has a high patient share for MMD?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Myopic Macular Degeneration prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender-specific diagnosed prevalence of MMD.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Myopic Macular Degeneration Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Myopic Macular Degeneration (MMD) cases in 2022?

The highest cases of Myopic Macular Degeneration was found in France among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Myopic Macular Degeneration (MMD) cases in 2022?

The highest cases of Myopic Macular Degeneration were found in Japan among the 7MM in 2022.